Chris Bleackley
Distinguished University Professor
Ph.D, Birmingham
Office: 780-492-3968
Lab: 780-492-4552
Fax: 780-492-0886
chris.bleackley@ualberta.ca
Research:
Selected Publications:
Design and characterization of a novel human Granzyme B inhibitor .
Marcet-Palacios M, Ewen C, Pittman E, Duggan B, Carmine-Simmen K, Fahlman RP, Bleackley RC.
Protein Eng Des Sel. 2015 Jan;28(1):9-17.
Cloning CTL-Specific Genes (And Now for Something Completely Differential).
Bleackley RC.
Front Immunol. 2014 Oct 14;5:509.
Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia.
Baginska J, Viry E, Berchem G, Poli A, Noman MZ, van Moer K, Medves S, Zimmer J, Oudin A, Niclou SP, Bleackley RC, Goping IS, Chouaib S, Janji B.
Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17450-5.
Granzyme B inhibits vaccinia virus production through proteolytic cleavage of eukaryotic initiation factor 4 gamma 3.
Marcet-Palacios M, Duggan BL, Shostak I, Barry M, Geskes T, Wilkins JA, Yanagiya A, Sonenberg N, Bleackley RC.
PLoS Pathog. 2011 Dec;7(12):e1002447.
Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells.
Thiery J, Keefe D, Boulant S, Boucrot E, Walch M, Martinvalet D, Goping IS, Bleackley RC, Kirchhausen T, Lieberman
J. Nat Immunol. 2011 Jun 19;12(8):770-7.
Granzyme H induces cell death primarily via a Bcl-2-sensitive mitochondrial cell death pathway that does not require direct Bid activation.
Ewen CL, Kane KP, Bleackley RC.
Mol Immunol. 2013 Jul;54(3-4):309-18.
Lab Members
Technologists
Diane Marganski
Links
Location
Office: 467a MSB
Lab: 467 MSB